[
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
    "bbox": [
      110,
      83,
      1000,
      95
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "disease).",
    "bbox": [
      110,
      113,
      177,
      127
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
    "bbox": [
      111,
      145,
      1000,
      158
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
    "bbox": [
      111,
      161,
      1000,
      173
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
    "bbox": [
      112,
      176,
      1000,
      188
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
    "bbox": [
      110,
      192,
      876,
      204
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
    "bbox": [
      111,
      223,
      637,
      235
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
    "bbox": [
      112,
      254,
      616,
      266
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
    "bbox": [
      110,
      284,
      1000,
      297
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
    "bbox": [
      112,
      300,
      1000,
      313
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
    "bbox": [
      112,
      317,
      957,
      328
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
    "bbox": [
      110,
      346,
      1000,
      359
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the Field in the Territory..",
    "bbox": [
      110,
      362,
      287,
      375
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
    "bbox": [
      110,
      393,
      1000,
      406
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "renewals thereof.",
    "bbox": [
      110,
      410,
      235,
      420
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
    "bbox": [
      111,
      440,
      590,
      453
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
    "bbox": [
      111,
      471,
      1000,
      483
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
    "bbox": [
      110,
      487,
      670,
      499
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
    "bbox": [
      111,
      534,
      1000,
      546
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
    "bbox": [
      111,
      580,
      1000,
      592
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
    "bbox": [
      111,
      596,
      1000,
      606
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of this Agreement..",
    "bbox": [
      111,
      612,
      247,
      623
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
    "bbox": [
      111,
      642,
      1000,
      654
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
    "bbox": [
      113,
      658,
      1000,
      670
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
    "bbox": [
      111,
      674,
      1000,
      685
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
    "bbox": [
      111,
      690,
      1000,
      701
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
    "bbox": [
      113,
      705,
      1000,
      717
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
    "bbox": [
      110,
      719,
      875,
      733
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
    "bbox": [
      133,
      1000,
      451,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]